PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer

NCT06335147 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

23

Enrollment

OTHER_GOV

Sponsor class

Conditions

Metastatic Colon Cancer

Interventions

DRUG: Serplulimab, mFOLFOX6

Sponsor

Henan Cancer Hospital